Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| DYN | PRESS-RELEASE | bullish | 7/10 | Dyne Therapeutics reported Q2 2026 net loss of $1.08 per share, slightly narrower than the $0.97 loss in Q2 2025 but abo | Jul 29, 2026 |
| ELAB | PRESS-RELEASE | neutral | 3/10 | PMGC Holdings confirms compliance with Nasdaq's new MVLS listing requirement as of July 29, 2026, and is working to corr | Jul 29, 2026 |
| ENTX | PRESS-RELEASE | neutral | 5/10 | No summary provided | Jul 29, 2026 |
| HCWB | PRESS-RELEASE | bearish | 6/10 | HCW Biologics priced a $1.6M private placement offering involving insider participation (CEO, Chairman, SVP), issuing 21 | Jul 29, 2026 |
| SPRC | PRESS-RELEASE | neutral | 3/10 | SciSparc's majority-owned subsidiary NeuroThera announced successful internal validation of a proprietary quantum sampli | Jul 29, 2026 |
| LQDA | PRESS-RELEASE | neutral | 1/10 | Liquidia Technologies, Inc. announced it will report its Q2 2026 results on August 12, 2026. | Jul 29, 2026 |
| RNXT | PRESS-RELEASE | neutral | 1/10 | RenovoRx, Inc. announced it will host a conference call on August 12 to discuss its Q2 2026 results. | Jul 29, 2026 |
| MNKD | PRESS-RELEASE | bullish | 6/10 | MannKind announced positive topline safety and tolerability results from its Phase 1b INFLO-1 study of nintedanib DPI (M | Jul 29, 2026 |
| ETON | PRESS-RELEASE | bullish | 5/10 | Eton Pharmaceuticals submitted a Prior Approval Supplement (PAS) to the FDA seeking to expand KHINDIVI (hydrocortisone) | Jul 29, 2026 |
| NKTR | PRESS-RELEASE | neutral | 1/10 | Nektar Therapeutics announced it will report its Q2 results on August 13, 2026. | Jul 28, 2026 |
| MEOH | PRESS-RELEASE | bearish | 7/10 | Methanex reported Q2 2026 Adjusted EBITDA of $577M, a record driven by higher methanol pricing from Middle East supply d | Jul 28, 2026 |
| PHGE | PRESS-RELEASE | bearish | 7/10 | BiomX amended a $1.25M promissory note with Water.IO, extending maturity to November 1, 2026, and issuing 800,000 restri | Jul 28, 2026 |
| PVLA | PRESS-RELEASE | neutral | 1/10 | Palvella Therapeutics Inc. announced it will host a conference call on August 4, 2026 to discuss its Q2 2026 results. | Jul 28, 2026 |
| HBIO | PRESS-RELEASE | neutral | 1/10 | Harvard Bioscience, Inc. announced it will host a conference call on August 11, 2026 to discuss its Q2 2026 results. | Jul 28, 2026 |
| KNSA | PRESS-RELEASE | bullish | 7/10 | Kiniksa reported Q2 2026 ARCALYST net product revenue of $243.6M (~55% YoY growth), beating consensus estimates of $226. | Jul 28, 2026 |
| CMND | PRESS-RELEASE | neutral | 3/10 | Clearmind Medicine announced completion of treatment for all 24 participants in Part A of its Phase I/II trial for CMND- | Jul 28, 2026 |
| CGON | PRESS-RELEASE | bullish | 7/10 | CG Oncology published Phase 3 BOND-003 Cohort C results for cretostimogene in BCG-unresponsive NMIBC in The Lancet Oncol | Jul 27, 2026 |
| DNLI | PRESS-RELEASE | neutral | 1/10 | Denali Therapeutics Inc. announced it will report its Q2 2026 results on August 6, 2026. | Jul 27, 2026 |
| ORGO | PRESS-RELEASE | bullish | 6/10 | Organogenesis published peer-reviewed RCT results showing Affinity plus standard of care significantly improved wound cl | Jul 27, 2026 |
| HROW | PRESS-RELEASE | neutral | 1/10 | Harrow, Inc. announced it will report its Q2 2026 results on August 10, 2026. | Jul 27, 2026 |
| TNXP | PRESS-RELEASE | neutral | 1/10 | Tonix Pharmaceuticals Holding Corp. announced it will report its Q2 2026 results on August 10, 2026. | Jul 27, 2026 |
| NMRA | PRESS-RELEASE | bullish | 7/10 | Neumora Therapeutics announced favorable pre-clinical toxicology results for NMRA-215, a brain-penetrant oral NLRP3 inhi | Jul 27, 2026 |
| LEGN | PRESS-RELEASE | neutral | 4/10 | Legend Biotech CEO Ying Huang stepped down effective July 24, 2026; Alan Bash, President of the CARVYKTI Business Unit, | Jul 27, 2026 |
| ARGX | PRESS-RELEASE | bullish | 7/10 | argenx is acquiring Forte Biosciences for $77/share in cash, total equity value ~$2.2B, an 86% premium to Forte's VWAP s | Jul 27, 2026 |
| AAPG | PRESS-RELEASE | neutral | 1/10 | Ascentage Pharma's Chairman and CEO, Dr. Dajun Yang, was ranked No. 3 in The Medicine Maker Power List 2026 Small Molecu | Jul 26, 2026 |
| OTLK | PRESS-RELEASE | bullish | 8/10 | Outlook Therapeutics received FDA approval for LYTENAVA (bevacizumab-vikg) for wet AMD, the first and only FDA-approved | Jul 24, 2026 |
| CDXS | PRESS-RELEASE | bearish | 6/10 | Codexis priced a dilutive underwritten public offering of 16,666,667 shares at $1.50/share, expected to raise ~$23.1M in | Jul 23, 2026 |
| SCTX | 3, PRESS-RELEASE | bullish | 7/10 | Scribe Therapeutics (SCTX) priced its upsized IPO of 8,580,000 shares at $15.00/share, raising $128.7M in gross proceeds | Jul 23, 2026 |
| LODE | PRESS-RELEASE | mixed | 5/10 | Comstock reported Q2 2026 EPS of -$0.16, missing consensus of -$0.12 by 35.8%, with no revenue disclosed. The quarter in | Jul 23, 2026 |
| KRYS | PRESS-RELEASE | neutral | 1/10 | Krystal Biotech, Inc. announced it will report its Q2 2026 results on August 3, 2026. | Jul 23, 2026 |